When did Medpace Holdings, Inc. report Q1 2026 earnings?

Medpace Holdings, Inc. (MEDP) reported Q1 2026 earnings on April 22, 2026 after market close.

What were Medpace Holdings, Inc.'s Q1 2026 revenue and EPS?

Medpace Holdings, Inc. reported revenue of $706.6M and diluted EPS of $4.28 for Q1 2026.

Did Medpace Holdings, Inc. beat estimates in Q1 2026?

Revenue beat the consensus estimate of $697.6M by $9.0M. EPS beat the consensus estimate of $3.74 by $0.54.

How did Medpace Holdings, Inc.'s Q1 2026 results compare year-over-year?

Compared to the same quarter a year prior, revenue grew 26.5% from $558.6M a year earlier and diluted EPS grew 16.6% from $3.67.

Where can I find Medpace Holdings, Inc.'s Q1 2026 SEC filings?

You can read the 8-K earnings release (0001668397-26-000017) and the 10-Q periodic report (0001668397-26-000019) directly on SEC EDGAR. The filing index links above go to sec.gov.

Medpace Holdings, Inc. MEDP Q1 2026 earnings

Reported April 22, 2026 · After market close

Revenue$706.6MBeat by $9.0M Diluted EPS$4.28Beat by $0.54

Revenue estimate$697.6M

EPS estimate$3.74

Next report

Jul 22, 2026 (in a month)

Revenue estimate$690.7M

EPS estimate$3.98

Financials

Q1 2026

Income statement

See full

Revenue$706.6M+26.5%

Operating income$141.5M+24.6%

Net income$123.9M+8.1%

EPS (diluted)$4.28+16.6%

Balance sheet

See full

Cash & equivalents$652.7M+47.9%

Total debt$146.1M-2.8%

Total equity$598.3M+0.8%

Total assets$2.1B+12.2%

Cash flow

See full

Operating cash flow$151.8M+20.6%

CapEx$6.8M-31.8%

Free cash flow$145.0M+25.1%

Valuation & ratios

Q1 2026

Valuation

See full

Market cap$13.63B+46.8%

Enterprise value$13.12B+45.9%

P/E29.6×+7.3×

P/S5.1×+0.8×

Profitability

See full

Operating margin21%-0.1pp

Net margin17.2%-2.1pp

FCF margin26.5%+1.5pp

Returns & leverage

See full

Return on equity77.3%+11.4pp

Debt / equity0.2×0.0×

Current ratio0.8×+0.1×

Segments

By product

See full

Oncology$237.6M+60.5%

Metabolic$201.2M+18.0%

Other$93.3M-2.6%

Cardiology$80.2M+46.1%

Central Nervous System$56.3M-3.5%

By segment

See full

Reportable Segment$706.6M+26.5%

Versus estimates

Revenue

Q1 2026$706.6MBeat by $9.0M

Q4 2025$708.5MBeat by $19.1M Q3 2025$659.9MBeat by $18.9M Q2 2025$603.3MBeat by $64.5M Q1 2025$558.6MBeat by $32.2M Q4 2024$536.6MMiss by $3.2M

Diluted EPS

Q1 2026$4.28Beat by $0.54

Q4 2025$4.67Beat by $0.48 Q3 2025$3.86Beat by $0.33 Q2 2025$3.10Beat by $0.12 Q1 2025$3.67Beat by $0.61 Q4 2024$3.67Beat by $0.71

Ask the moment Medpace Holdings, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Medpace Holdings, Inc. report Q1 2026 earnings?: Medpace Holdings, Inc. (MEDP) reported Q1 2026 earnings on April 22, 2026 after market close.
What were Medpace Holdings, Inc.'s Q1 2026 revenue and EPS?: Medpace Holdings, Inc. reported revenue of $706.6M and diluted EPS of $4.28 for Q1 2026.
Did Medpace Holdings, Inc. beat estimates in Q1 2026?: Revenue beat the consensus estimate of $697.6M by $9.0M. EPS beat the consensus estimate of $3.74 by $0.54.
How did Medpace Holdings, Inc.'s Q1 2026 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 26.5% from $558.6M a year earlier and diluted EPS grew 16.6% from $3.67.
Where can I find Medpace Holdings, Inc.'s Q1 2026 SEC filings?: You can read the 8-K earnings release (0001668397-26-000017) and the 10-Q periodic report (0001668397-26-000019) directly on SEC EDGAR. The filing index links above go to sec.gov.